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ABSTRACT  
Background 
Pharmacists play important role in ensuring timely care delivery at the ward level. The optimal level of 
pharmacist input, however, is not clearly defined.  
Objective 
To systematically review the evidence that assessed the outcomes of ward pharmacist input for people admitted 
with acute or emergent illness. 
Methods 
The protocol and search strategies were developed with input from clinicians. Medline, EMBASE, Centre for 
Reviews and Dissemination, The Cochrane Library, NHS Economic Evaluations, Health Technology 
Assessment and Health Economic Evaluations databases were searched.   
Inclusion criteria specified the population as adults and young people (age >16 years) who are admitted to 
hospital with suspected or confirmed acute or emergent illness. Only randomised controlled trials (RCTs) 
published in English were eligible for inclusion in the effectiveness review. Economic studies were limited to 
full economic evaluations and comparative cost analysis. Included studies were quality-assessed. Data were 
extracted, summarised. and meta-analysed, where appropriate.  
Results 
Eighteen RCTs and 7 economic studies were included. The RCTs were from USA (n=3), Sweden (n=2), 
Belgium (n=2), China (n=2), Australia (n=2), Denmark (n=2), Northern Ireland, Norway, Canada, UK and 
Netherlands. The economic studies were from UK (n=2), Sweden (n=2), Belgium and Netherlands. The results 
showed that regular pharmacist input was most cost effective. It reduced length-of-stay (mean= -1.74 days [95% 
CI: -2.76, -0.72], and increased patient and/or carer satisfaction (Relative Risk (RR) =1.49 [1.09, 2.03] at 
discharge). At £20,000 per quality-adjusted life-year (QALY)-gained cost-effectiveness threshold, it was either 
cost-saving or cost-effective (Incremental Cost Effectiveness Ratio (ICER) =£632/ QALY-gained). No evidence 
was found for 7-day pharmacist presence. 
Conclusions 
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Pharmacist inclusion in the ward multidisciplinary team improves patient safety and satisfaction and is cost-
effective when regularly provided throughout the ward stay. Research is needed to determine whether the 
provision of 7-day service is cost-effective. 
KEY WORDS 
Clinical pharmacy, Systematic review, Meta-analysis, Cost effectiveness, acute medicine 
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1 
INTRODUCTION 1 
Adverse drug events (ADEs) are common in clinical settings, with a reported incidence from 2.3% in paediatric 2 
inpatients to 27.4% in adult outpatients.1 2 In adult inpatients, the reported incidence is 6.5%.3 These ADEs are 3 
direct causes of patient harm, dissatisfaction, prolonged hospital stay and increased costs. Pharmacists are 4 
considered the medication experts in the health care team. Their extensive training in and knowledge of 5 
pharmacology and therapeutics have placed them in the best position to undertake this role and to advise other 6 
health care professionals on matters relating to appropriate prescribing and safe use of medicines.4 7 
The pharmacist role in the hospital setting has evolved over the years, moving from a wholly dispensary-based 8 
role to a more clinically-focused one based on the ward.5 In fact, the presence of a ward-based pharmacist has 9 
become common practice in the UK.6   More recently, pharmacists have been granted the authority to prescribe 10 
medications in a number of countries including the UK and Canada.7 This has allowed clinical pharmacists who 11 
practise in hospitals to be more directly involved in patient care.  12 
In the UK, medical wards have access to some level of pharmacist input; however, the pharmacist may be 13 
responsible for covering several areas concurrently, limiting the level of detail they can bring to medicines 14 
management and patient and staff communication.6 This is particularly important for an ageing population with 15 
multiple co-morbidities for whom polypharmacy adds complexity and may indeed be the cause of the acute 16 
admission.8 Additionally, it has been argued that the input of a ward-based pharmacist, particularly at discharge, 17 
can improve patient flow by expediting the discharge process and alleviating the pressure that the “exit block”, 18 
created by delayed discharge, can have on emergency department performance and the emergency access target 19 
achievement.9 20 
In 2014, the National Institute for Health and Care Excellence (NICE) was commissioned to develop a guideline 21 
to advise the National Health Service (NHS) in England on various aspects of the delivery of emergency and 22 
acute medical care services.10 One of the aspects identified as a priority to be examined in the guideline was the 23 
role of ward-based pharmacists with the aim of assessing the impact of their interventions on improving patient 24 
and process outcomes in the acute and emergency medical care pathway within NHS hospitals.  25 
Hence, this systematic review was undertaken as part of the guideline development process to assess the 26 
outcomes of ward-based pharmacists’ interventions for patients admitted to hospital with a suspected or 27 
confirmed acute medical emergency.  28 
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2 
METHODS 29 
A systematic literature review was undertaken to synthesise the evidence that assessed the effectiveness and 30 
cost-effectiveness of the presence of ward-based pharmacists for patients with a suspected or confirmed acute 31 
medical emergency. It was undertaken in accordance with the standard methods for reviewing the clinical and 32 
economic evidence specified in the NICE guidelines development manual.11 No ethics approval was required for 33 
this work. 34 
Protocol development 35 
The protocol for reviewing the effectiveness evidence was developed and approved by the guideline 36 
development group (GDG), a team of experts consisting of 19 health care professionals including acute care 37 
clinicians and a pharmacist in addition to two lay members and a technical team. The protocol specified the 38 
inclusion and exclusion criteria (including the population, interventions and comparators, outcomes and study 39 
design). These are briefly outlined below (Box 1).  40 
The protocol for reviewing the economic evidence was aligned with this in terms of the population, 41 
interventions and comparators. Full economic evaluations (studies comparing costs and health consequences of 42 
alternative courses of action which include cost-utility, cost-effectiveness, cost-benefit and cost-consequences 43 
analyses) and comparative costing studies that addressed the review question in the relevant population were 44 
considered potentially includable as health economic evidence. 45 
Exclusion criteria for the economic review included the following: 46 
1- Economic studies that only reported cost per hospital (not per patient), or only reported average cost-47 
effectiveness without disaggregated costs and effects. 48 
2-  Studies published before 2005, because health services change rapidly and therefore the costs and 49 
benefits of treatments soon become out of date. 50 
3- Studies from non-OECD countries or the USA were also excluded, on the basis that the applicability of 51 
such studies to the present UK NHS context is likely to be too low for them to be helpful for decision-52 
making.  53 
Remaining health economic studies were prioritised for inclusion based on their relative applicability to the 54 
guideline context and the study limitations (see Quality Assessment below). 55 
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3 
The clinical and economic review protocols are presented in Appendix 1 in the Supplementary Material. 56 
 57 
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4 
  58 
Box 1: Population, Intervention, Comparator, Outcomes (PICO) and 
inclusion/exclusion criteria of the clinical review 
 Population 
The population of interest was defined as adults and young people (16 years and over) 
admitted to hospital with a suspected or confirmed acute medical emergency (AME). 
Interventions and comparators 
The intervention was defined as “presence of medical ward-based pharmacists” and the 
comparator as “No ward-based pharmacists”. The intervention was further stratified as 
either for less than 7 days a week or for 7 days a week. 
Outcomes 
-Mortality during the study period,  
-Avoidable adverse events during the study period,  
-Quality of life during the study period,  
-Patient and/or carer satisfaction during the study period,  
-Length of stay in hospital during the study period,  
-Readmissions within 30 days, future admissions to hospital (over 30 days),  
-Discharges during the study period,  
-Prescribing errors during the study period,  
-Missed medications during the study period,  
-Medicines reconciliation during the study period,  
-Staff satisfaction during the study period. 
 
Inclusion and exclusion criteria 
The key population inclusion criterion was: 
• Adults (18 years and over) and young people (16-17 years) who seek, or are 
referred for, emergency NHS care for a suspected or confirmed acute medical 
emergency.  
The key population exclusion criteria were: 
• Children 
• People with acute obstetric emergencies 
• People with acute metal health emergencies, once a diagnosis has been made 
• People with acute surgical emergencies, once a diagnosis has been made 
• People who have experienced major trauma, complex or non-complex fractures 
or spinal injury 
• People in hospital who are not there for an acute medical emergency (i.e. elective 
admissions) and do not develop an acute medical emergency during their stay 
• People already in hospital with acute deterioration 
• People with chronic conditions who are being managed as outpatients but who 
require an elective admission for treatment form specialists who may be involved 
in the acute pathway.  
Literature reviews, posters, letters, editorials, comment articles, unpublished studies and 
studies not in English were excluded. 
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5 
Information sources and search strategies 59 
Databases were searched using relevant medical subject headings, free-text terms and study-type filters where 60 
appropriate. Searches were restricted to papers published in English and were conducted in Medline, EMBASE, 61 
Centre for Reviews and Dissemination (CRD) and The Cochrane Library.  62 
The economic evidence was identified by conducting a search in Medline and EMBASE, using economic filters. 63 
Searches were also conducted in the economics-specific databases NHS Economic Evaluation Database (NHS 64 
EED) and Health Technology Assessment database (HTA); which were searched via CRD.  65 
Search strategies were quality assured by cross-checking reference lists of highly relevant papers, analysing 66 
search strategies in other systematic reviews, and asking the GDG members to highlight any additional studies. 67 
Searches were quality assured by a second information scientist before being run and were updated in December 68 
2016. All search strategies are listed in Appendix 2 of the Supplementary Material. 69 
Study selection 70 
The titles and abstracts of records retrieved were sifted for relevance, with potentially significant publications 71 
obtained in full text. These were assessed against the inclusion criteria (see the review protocols in Appendix 1 72 
of the supplementary materials). For the effectiveness evidence, parallel randomised controlled trials (RCTs) 73 
were included. A sample of 10% of the abstract lists was double-sifted by a second reviewer and any 74 
discrepancies were rectified.  75 
Data extraction and synthesis 76 
Data were extracted from the included studies into standard evidence tables. Meta-analyses of the efficacy data 77 
were conducted using Cochrane Review Manager (RevMan5)2 software to combine the data given in all studies 78 
for each of the outcomes of interest. Fixed-effects (Mantel-Haenszel) techniques (using an inverse variance 79 
method for pooling) were used to calculate risk ratios (relative risk (RR)) for the binary outcomes, which 80 
included: mortality, admission, readmission and adverse events. The absolute risk difference was calculated 81 
using GRADEpro software, 12 using the median event rate in the control arm of the pooled results. For binary 82 
variables where there were zero events in either arm or a less than 1% event rate, Peto odds ratios, rather than 83 
risk ratios, were calculated.  84 
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6 
Continuous outcomes were analysed using an inverse variance method for pooling weighted mean differences. 85 
These outcomes included: quality of life, length of stay in hospital (LOS), patient and/or carer satisfaction. 86 
Where the studies within a single meta-analysis had different scales of measurement, standardised mean 87 
differences were used (providing all studies reported either change from baseline or final values rather than a 88 
mixture of both); each different measure in each study was ‘normalised’ to the standard deviation value pooled 89 
between the intervention and comparator groups in that same study.  90 
Statistical heterogeneity was assessed by considering the chi-squared test for significance at p<0.1 or an I-91 
squared (I2) inconsistency statistic (with an I-squared value of more than 50% indicating significant 92 
heterogeneity) as well as the distribution of effects. Where significant heterogeneity was present, predefined 93 
subgrouping of studies was carried out as per the protocols.  94 
 95 
NICE economic evidence profile tables were used to summarise cost and cost-effectiveness estimates from the 96 
included studies. These show the incremental costs, incremental effects (for example, quality-adjusted life-years 97 
[QALYs]) and incremental cost-effectiveness ratio (ICER) for the base-case analysis in the study, as well as 98 
information about the assessment of uncertainty in the analysis. When a non-UK study was included, the results 99 
were converted into pounds sterling using the appropriate purchasing power parity.13 Cost effectiveness was 100 
assessed based on a cost-effectiveness threshold of £20,000 per QALY gained; in line with the NICE reference 101 
case; where ICERs less than the specified threshold indicate cost effectiveness.11 102 
Quality assessment 103 
The evidence for outcomes from the included RCTs were evaluated using an adaptation of the ‘Grading of 104 
Recommendations Assessment, Development and Evaluation (GRADE) toolbox’ developed by the international 105 
GRADE working group (http://www.gradeworkinggroup.org/). The software (GRADEpro) was used to assess 106 
the quality of the evidence for each outcome, taking into account individual study quality and the meta-analysis 107 
results.12 Each outcome was first examined for each of the quality elements (see Supplementary material, 108 
Appendix 3, Table 3.1 for details). Publication bias was only taken into consideration in the quality assessment 109 
if it was apparent. 110 
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7 
The methodological quality of the economic evidence and its applicability to the UK context were assessed 111 
using the economic evaluation checklist from the NICE guidelines manual,  and included in the economic 112 
evidence profile (see Appendix 3 in the Supplementary Material for the possible ratings for each dimension and 113 
their criteria).11 114 
Patient involvement 115 
Two lay members were part of the guideline development group and contributed to the development of the 116 
review protocol. The choice of the outcome measures was informed by their views of which outcomes were 117 
critical from a patient perspective. The analysis methods and results were regularly presented to and validated 118 
by all the group members including the two lay members. 119 
RESULTS 120 
The search for RCTs retrieved 3196 records. Of these, 20 papers reporting on 18 RCTs were included in the 121 
review. 14-33 A list of the excluded studies with reasons for exclusion are presented in Appendix 4 in the 122 
Supplementary Material. The economic search retrieved 918 records, of which 7 papers reporting on 7 studies 123 
were included.17 21 34-38  The PRISMA flow diagrams of both searches are presented in Appendix 5, Figure 5.1 124 
and Figure 5.2.  125 
The studies were split into 3 strata: regular ward-based pharmacist input (where the ward-based pharmacist 126 
provided interventions throughout the patient stay on the ward, which included both admission and discharge 127 
services), pharmacist input at admission, and pharmacist input at discharge. The interventions and comparators 128 
were often not well defined and there was variation across the studies in their composition.  129 
The characteristics of the included RCTs and economic studies are summarised in Tables 1 and 2, respectively.  130 
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Table 1: Characteristics of the included studies- clinical evidence  
Study Country Population 
Study 
design Intervention Comparator Outcomes 
1.Regular ward-based pharmacist input 
Claus 201417 
 
 
Belgium Surgical ICU admissions (n=69) 
within a university hospital. 
 
Inclusion - over 16 years of age, 
length of stay greater than 48 
hours. 
 
Exclusion - none stated. 
 
RCT Pharmacist present on 
the ward. Duties 
included making 
active 
recommendations and 
performing patient 
follow-up. 
Pharmacist is present 
on the ward but 
recommendations 
were not passed on to 
the primary care 
giver.  
In-hospital mortality. 
Iowa 
Continuity of 
Care Study 
trial: Farris 
2014 (Farley 
2014)19 20 
 
 
USA General medicine, family 
medicine, cardiology or 
orthopaedic admissions (n=631) 
within an academic tertiary care 
hospital. 
 
Inclusion - patients with certain 
disease classifications: 
hypertension, hyperlipidaemia, 
heart failure, coronary artery 
disease, myocardial infarction, 
stroke, transient ischemic attack, 
asthma, chronic obstructive 
pulmonary disease or receiving 
oral anticoagulation. 
RCT Pharmacy case 
manager. Duties 
included medication 
reconciliation, ward 
visits and discharge 
service. 
 
 
 
 
Nurse based 
medication 
reconciliation and 
discharge service. 
Preventable adverse 
drug events in-
hospital; post-
discharge (90 days) 
hospital Readmission 
at 30 days; 
Admission at 
90 days  
Medication 
appropriateness index 
(MAI) at discharge; 30 
days; 90 days. 
Gillespie 
200921 
 
Sweden Patients (n=400) admitted to the 
2 acute internal study wards at a 
University teaching hospital.  
RCT Pharmacist present on 
the ward. Duties 
included taking part in 
the rounding team, 
No pharmacist 
involvement in the 
healthcare team at 
Overall survival at 12 
months, reported as 
hazard ratio. 
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Study Country Population 
Study 
design Intervention Comparator Outcomes 
  
Inclusion - 80 years of age. 
 
Exclusion - previously been 
admitted to the study wards 
during the study period or had 
scheduled admissions. 
documenting 
medication history, 
and discharge 
counselling. 
 
 
the ward level.  
Admission at 12 
months 
Kucukarslan 
2003 23 
 
 
USA All patients (n=165) admitted to 
1 of the 2 internal medicine 
study wards within a tertiary 
care hospital. 
 
Inclusion - admitted to the 
internal medicine service and 
remained in the same patient 
care unit until discharge. 
 
Exclusion – none given.  
Quasi-
RCT 
Pharmacist present on 
the ward. Duties 
included taking part in 
the rounding team, 
documenting 
medication history, 
and discharge 
counselling. 
 
Standard care from 1 
pharmacist 
(implication in paper 
that this is not ward-
based). 
Avoidable adverse 
drug events until 
discharge. 
 
Length of stay in-
hospital (reported as 
mean difference). 
 
Re-admission (unclear 
follow-up time, 
reported as percentage 
reduction). 
Shen 2011 29 
 
 
China  
 
n=354 inpatients in 2 respiratory 
wards diagnosed with 
respiratory tract infections. 
 
Exclusion: transferred from 
other medical departments; 
transferred to other medical 
departments for further 
treatment; already received 
antibiotics before admission; did 
RCT Clinical pharmacist 
part of the treating 
team – communicated 
any potentially 
inappropriate 
antibiotic use 
(indication, choice, 
dosage, dosing 
schedule, duration, 
conversion) with the 
Standard treatment 
strategies performed 
by the physicians and 
nurses without 
pharmacist 
involvement. 
Length of stay.  
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Study Country Population 
Study 
design Intervention Comparator Outcomes 
not receive antibiotics during 
hospitalisation.  
physician to discuss 
and make 
recommendations.  
Scullin 200728 
 
 
  
Northern 
Ireland 
Admitted patients (n=762) to the 
4 medical study wards within 3 
general hospitals.  
 
Inclusion: taking at least 4 
regular medication, were taking 
a high risk drug(s), were taking 
antidepressants and were 65 
years old or older, had a hospital 
admission within the last 6 
months, prescribed antibiotics 
on day 1 of admission. 
 
Exclusion - scheduled 
admissions and patients 
admitted from private nursing 
homes. 
RCT Pharmacist present on 
the ward. Duties 
included admission 
services, in-patient 
monitoring, and 
discharge services 
 
Traditional clinical 
pharmacy services 
(no further details 
given). 
Admission at 12 
months. 
 
Mortality at 12 
months. 
 
Length of stay. 
Spinewine 
200730 
 
 
 
Belgium All eligible patients (n=186) 
admitted to the Geriatric 
Evaluation and Management 
(GEM) unit within a university 
teaching hospital. 
 
GEM unit accepted patients over 
70 years of age. 
RCT Pharmacist present on 
the ward. Duties 
included taking part in 
the rounding team, 
documenting 
medication history, 
and discharge 
counselling. 
Usual care (no 
details of any clinical 
pharmacist 
involvement). 
Rate of death at 1 year 
follow-up.  
 
Satisfaction with 
information received. 
 
Admission at 12 
months. Medical 
appropriateness index. 
Zhao 2015 & China n=90 patients admitted to the RCT Interventions by Conventional Avoidable adverse 
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Study Country Population 
Study 
design Intervention Comparator Outcomes 
Zhao 2015B32 
33
 
 
 
cardiology ward in a hospital. 
 
Inclusion: diagnosis of CHD by 
physician, accepted ≥4 kinds of 
drugs, ≥18 years, primary high 
school education, able to 
complete the study, available for 
telephone follow up. 
 
Exclusion: pregnant/lactating 
women, patients enrolled in 
other studies, severe co-
morbidities, family history of 
psychosis, and barriers to 
communication. 
clinical pharmacists 
including individual 
drug regimens, 
attending daily 
medical rounds, 
advice to physicians, 
education of medical 
staff, patient education 
on lifestyle changes, 
psychological 
interventions such as 
stress reduction, 
medication 
counselling at 
discharge, monthly 
follow up telephone 
calls post-discharge. 
medical treatment 
without pharmacist 
participation. 
events (adverse drug 
reactions). 
 
Patient and/or carer 
satisfaction.  
 
2. Ward-based pharmacist input at admission 
Aag 201414 
 
 
Norway Consecutively admitted patients 
(n=201) to the Cardiology study 
ward at a University hospital. 
 
Inclusion - aged 18 and over. 
 
Exclusion - terminal illness, 
isolated due to an infectious 
disease, unable to communicate 
in either Norwegian or English.  
RCT Pharmacist medication 
reconciliation. 
 
 
 
Nurse medication 
reconciliation. 
Medication 
discrepancies 
identified at 
admission. 
 
Prescribing physician 
agreement to act upon 
medication 
discrepancies 
identified 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
 
 
 
12
Study Country Population 
Study 
design Intervention Comparator Outcomes 
Khalil 2016 22 
 
 
Australia n=110 adult medical patients 
admitted to the acute assessment 
and admission (AAA) unit via 
the ED during pharmacy 
operating hours (8.30am – 5pm). 
 
Exclusion: not admitted to the 
AAA ward within 24 hours; no 
medications prior to admission; 
not a general medical patient. 
RCT Pharmacist-initiated 
medication 
reconciliation – 
pharmacist obtained a 
‘best possible 
medication history’ 
from the patient 
and/or other sources, 
undertook admission 
medication 
reconciliation, 
reviewed current 
medications and the 
need for new 
medications in relation 
to the admission 
diagnosis, developed a 
medication 
management plan with 
the referring senior 
medical officer and 
charted on the 
electronic medication 
administration record 
Usual care – 
medication orders 
charted by medical 
staff. 
Prescribing errors.  
 
 
Lind 2016 24 
 
 
Denmark n=448 patients arriving at the 
acute admission unit on 
weekdays 9am-4.15pm. 
 
RCT Clinical pharmacist 
intervention - 
obtaining medication 
history (using a 
Standard care – on 
arrival, patients 
triaged by a nurse, 
then seen by a 
Length of stay on the 
acute admission unit 
(defined as interval in 
minutes between 
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Study Country Population 
Study 
design Intervention Comparator Outcomes 
Inclusion: ≥18 years, taking ≥4 
drugs daily (including over-the-
counter, herbals and 
supplements).  
 
Exclusion: terminal or 
intoxicated; assigned to triage 
level 1; referred to acute 
outpatient clinic; unable to give 
informed consent; interviewed 
by physician prior to giving 
informed consent; unexpected 
overnight stay.  
minimum of 2 
sources, 1 of which 
was an interview with 
the patient and/or 
relatives where 
possible), entering 
prescriptions into the 
electronic medication 
module (EMM), 
medication 
reconciliation, 
reviewing overall 
medication treatment 
and writing a note in 
the electronic medical 
record. 
physician who was 
responsible for 
obtaining medication 
history, reconciling 
and assessing 
medication treatment 
and entering 
prescriptions in the 
EMM. 
arrival and discharge 
or transfer to a hospital 
ward). 
Lisby 201025 
 
  
Denmark Consecutively admitted patients 
(n=100) to acute internal 
medicine study ward within 1 
regional hospital. 
 
Inclusion - patients were 70 
years or older. 
RCT 
 
Pharmacist admission 
review. 
 
 
Senior physician 
admission review. 
Self-experienced 
quality of health at 3 
months. 
 
Length of stay in 
hospital. 
 
Admission rate at 3 
months. 
 
Mortality. 
Nester 200226 USA Consecutively admitted patients 
(n=100) to a tertiary care 
Quasi-
RCT 
Pharmacist medication 
reconciliation. 
Nurse medication 
reconciliation. 
Medication 
discrepancies 
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Study Country Population 
Study 
design Intervention Comparator Outcomes 
 
 
referral centre. 
 
Inclusion - over 18, responsive 
and able to speak English. 
 
Exclusion - intensive care, 
ambulatory surgical and labour-
and-delivery units. 
 
 
 
identified at 
admission. 
 
Tong 201631 
 
 
Australia n=881 patients admitted to the 
general medical unit (GMU) and 
emergency short stay unit 
(ESSU) during pharmacist 
working hours (7am-9pm). 
 
Exclusion: medication chart 
written by a doctor before 
pharmacist review; admitted to 
ESSU and not reviewed by a 
pharmacist. 
RCT Early medication 
review and charting 
on admission 
involving a 
partnership between a 
pharmacist and a 
medical officer – 
pharmacist took 
medical history, VTE 
risk assessment and 
discussed medical and 
medication problems 
with admitting 
medical officer to 
agree a medication 
management plan. 
Standard medication 
charting by medical 
officers of relevant 
teams, with 
subsequent 
medication 
reconciliation 
performed by 
pharmacist within 24 
hours of admission. 
Prescribing errors.  
3. Ward-based pharmacist input at discharge 
Al-Rashed 
2002 15 
 
UK n=83 patients admitted to 2 care 
of the elderly wards. 
 
RCT Pre-discharge 
counselling (24 hours 
before discharge) by 
Normal hospital 
discharge policy – all 
patients, their GPs, 
Readmission.  
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Study Country Population 
Study 
design Intervention Comparator Outcomes 
 Inclusion: >65 years, prescribed 
4 or more regular items, were to 
be discharged to their own home 
and had an abbreviated mental 
score >7/10, English as a first 
language, and routine clinical 
pharmacist assessment that they 
could have problems with their 
medicines after discharge. 
the clinical pharmacist 
attached to that ward. 
 
 
district nurses and 
carers received a 
copy of the patient’s 
medication and 
information 
discharge summary 
sheet (MIDS) and 
patients received a 
medicine reminder 
card. Nurse went 
through (MIDS) with 
patients. 
Bladh 201116 
 
  
Sweden Patients (n=345) admitted on 
weekdays to the 2 internal 
medicine study wards at a 
university hospital. 
 
Inclusion - capable of assessing 
their HRQL and giving written 
informed consent. 
 
Exclusion - poor Swedish 
language, planned discharge 
before intervention can be 
performed, transferred during 
their stay to other hospitals or 
wards not belonging to the 
Department of Medicine. 
RCT Pharmacist discharge 
review 
 
Usual care, which 
was received from 
the same group of 
physicians and 
nurses. No other 
details given. 
EQ-5D summarised 
index at 6 months 
follow-up. 
Eggink 201018 Netherlands Patients (n=89) to be discharged 
(no criteria given) in the 
RCT Pharmacist discharge Nurse discharge Prescription errors 
identified during first 
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Study Country Population 
Study 
design Intervention Comparator Outcomes 
 
  
Cardiology study ward within a 
teaching hospital. 
 
Inclusion - patients have 
prescribed 5 or more medicines 
(from any class) at discharge. 
 
Exclusion - none stated. 
review. 
 
 
 
review. outpatient follow-up. 
Nickerson 
2005 27 
 
 
Canada n=253 patients admitted to 2 
family practice units. 
 
Inclusion: not discharged to 
another hospital, prescribed at 
least 1 medication at discharge, 
provided consent, agreement 
from community pharmacy, no 
previous study enrolment. 
 
Exclusion: unable to answer 
study questions, unavailable for 
follow-up.  
RCT Seamless care 
pharmacist at 
discharge including 
medication 
reconciliation, review 
of drug regime as part 
of comprehensive 
pharmaceutical care 
work-up, 
identification of 
problems and 
communication to 
community pharmacy, 
hospital staff and 
family physician, 
medication discharge 
counselling and a 
medication 
compliance chart  
Standard care at 
discharge - discharge 
counselling and 
manual transcription 
of discharge notes 
from medical chart 
by nurse. 
Prescriber errors- 
unresolved drug 
therapy inconsistencies 
and omissions.  
Abbreviations: CHD: chronic heart disease; EQ-5D: EuroQol 5 Dimensions questionnaire;  GP: general practitioner; RCT: randomised controlled trial,
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Table 2: Characteristics of the included studies- economic evidence 1 
Study Country Population Study design 
Follow-up/time 
horizon Intervention 1 Intervention 2 
1. Regular ward-based pharmacist input 
Claus 2014.17 Belgium Critically ill patients 
(>16 years of age and 
with minimum length 
of ICU stay of 2 days) 
and in a 22-bed, 
surgical ICU at Ghent 
University Hospital, 
Belgium.  
Within RCT analysis 
of individual patient 
level data 
 
Cost-effectiveness 
analysis 
 
Length of ICU 
stay 
No clinical 
pharmacist direct 
involvement in 
patient care 
A clinical pharmacist 
is directly involved 
in patient care 
 
Ghatnekar 2013 
35
 
Sweden Elderly hospital 
inpatients at Skane 
University Hospital in 
Lund, Sweden 
  
Decision tree model 
 
Cost-utility analysis 
3 months Standard care (not 
defined) 
Multidisciplinary 
team including 
clinical pharmacist 
undertakes 
systematic 
medication review 
and reconciliation 
from admission to 
discharge (the Lund 
Integrated Medicines 
Management 
[LIMM]) 
Gillespie 200921 Sweden Elderly inpatients (80 
years or older) 
admitted to 2 acute 
internal medicine 
wards at a University 
Hospital of Uppsala, 
Within-RCT analysis 
 
Cost-effectiveness 
analysis 
12 months No pharmacist 
involvement in the 
healthcare team at 
the ward level.  
Pharmacist present 
on the ward. 
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Study Country Population Study design 
Follow-up/time 
horizon Intervention 1 Intervention 2 
Sweden. 
Karnon 2008 36 UK inpatients at 400 beds 
acute hospital (average 
hospital size) with 
around 14 wards  
Decision tree model 
 
 
Cost-utility analysis 
5 years No ward-based 
pharmacist (a 
pharmacist covers 2 
wards of about 30 
patients over a 
morning to provide 
basic level of 
pharmaceutical care 
and in the afternoons 
they have 
departmental 
commitments) 
Ward-based senior 
pharmacist (grade 
7/8a) attends rounds 
with residents, 
nurses, attending 
staff each morning; 
is present in the ward 
for consultation and 
assistance to nursing 
staff during the rest 
of the morning and is 
available on call as 
necessary during the 
rest of the day. 
Klopotowska 
201037 
Netherlands Patients in an adult 
surgical and medical 
28-bed ICU of an 
academic medical 
centre 
   
 
Before and after 
comparative 
interventional study 
Cost-consequences 
analysis 
 
Length of ICU 
stay. 
Standard pharmacy 
services provided by 
the hospital 
pharmacy 
department. 
Two experienced 
hospital pharmacists 
present on the ICU 
daily and attending 
multidisciplinary 
patient review 
meeting. 
2. Ward-based pharmacist input at admission 
Fertleman 
200534 
UK Medical patients 
admitted within the 
preceding 24 hours to 
a general medical ward 
Before-and-after 
observational study 
Comparative cost 
3 days Ward-based 
pharmacist provide 
pharmaceutical care 
for 1-2 hours at some 
Senior pharmacist 
present on post-
admission (post-take) 
ward rounds (PTWR) 
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Study Country Population Study design 
Follow-up/time 
horizon Intervention 1 Intervention 2 
at a district general 
hospital (Northwick 
Park hospital in north-
west London) 
analysis time during the day 
(usual care) 
 
in addition to the 
usual care 
3. Ward-based pharmacist input at discharge 
Wallerstedt 
201238 
Sweden Elderly inpatients on 2 
internal medicine 
wards at Sahlgrenska 
University Hospital, 
Sweden.    
Within-RCT analysis 
(linked trial: Bladh 
2011) 
 
Cost-utility analysis 
6 months Usual care, which 
was received from 
the same group of 
physicians and 
nurses. 
Clinical pharmacists 
delivering a 
composite 
intervention 
consisting of 
medication review 
including feedback to 
physicians on 
prescribing, drug 
treatment discussion 
with the patient at 
discharge, 
medication report 
including summary 
of drug treatment 
changes to be sent to 
the GP 
Abbreviations: GP: general practitioner; ICU: intensive care unit; RCT: randomised controlled trial 2 
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Regular ward-based pharmacist input 4 
Eight RCTs (n= 2,303) evaluated the outcomes of the presence of a ward-based pharmacist providing regular 5 
input.17 19-21 23 28-30 32 33 In these studies, the pharmacist in the intervention arm was involved in all stages of the 6 
patient journey from admissions to monitoring, follow-up and discharge. The evidence suggested reduced 7 
mortality (RR= 0.92 (95% CI: 0.72 to 1.16), 3 studies, very low quality), reduced preventable ADEs in hospital 8 
(RR= 0.74 (95% CI: 0.06 to 8.57), 2 studies, very low quality) and at 90 days follow up (RR= 0.77 (95% CI: 9 
0.29 to 2.05), 1 study, very low quality), reduced LOS (-1.74 days (95% CI: -2.76 to -0.72), 2 studies, moderate 10 
quality), reduced prescribing errors at discharge (- 0.02 (95% CI: -0.12 to 1.08), 2 studies, low quality) and 11 
increased patient and/or carer satisfaction at discharge (RR= 1.49 (95% CI: 1.09 to 2.03) and at one month 12 
follow-up (RR= 1.79 (95% CI: 1.38 to 2.32), 1 study, low quality). It also reduced hospital admission (RR= 0.93 13 
(95% CI: 0.83 to 1.04), 4 studies, moderate quality) and readmission (RR= 0.92 (95% CI: 0.62 to 1.37), 1 study, 14 
very low quality). However, there were increased prescribing errors (measured by medication appropriateness 15 
index) at 30 days (2.1 higher (95% CI: 0.45 to 3.75 higher), 1 study, moderate quality) and adverse drug events 16 
at 3 to 6 months post discharge (RR= 1.47 (0.26 to 8.33), 1 study, very low quality). The results are summarised 17 
in the clinical evidence profile in Table 5.3 and the Forest plots presented in Appendices 5 and 6 of the 18 
Supplementary Materials, respectively. 19 
Five economic evaluations were included in this stratum.17 21 35-37 These were conducted in Belgium (n=3), 20 
Netherland (n=1) and the UK (n=1). Three studies reported that the ward-based pharmacist input was dominant 21 
(more effective and less costly) compared to usual care. One cost-utility analysis (CUA) showed that the ward-22 
based pharmacist intervention was cost-effective with an ICER of £632 per QALY-gained. One study showed 23 
that regular ward-based pharmacist input was less effective and less costly, with no clear conclusion regarding 24 
cost effectiveness given the absence of a cost-effectiveness threshold for the reported outcomes. All five studies 25 
were assessed as partially applicable with potentially serious limitations. The results are summarised in Table 26 
5.4, Appendix 5 and the quality assessment rationale in Appendix 7 in the Supplementary Material. 27 
Ward-based pharmacist input at admission 28 
Six RCTs (n=401) evaluated the role of pharmacists at admission for improving outcomes.14 22 24-26 31 The 29 
pharmacists in the intervention arms in these studies were mainly involved at the admission stage of the patient 30 
journey, for example participating in post-take ward rounds, medicines reconciliation and taking medication 31 
history. The evidence suggested that pharmacist input at admission may provide benefit in improving 32 
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identification of medication discrepancies during medicines’ reconciliation at admission (+0.36 (95% CI: 0.07 33 
to 0.65), 2 studies, low quality), reducing medication errors within 24 hours of admission (RR= 0.05 (95% CI: 34 
0.03 to 0.08), 1 study, moderate quality) and increasing physician agreement to act upon medication 35 
discrepancies identified (RR= 1.35 (95% CI: 1.13 to 1.63), 1 study, very low quality). However, there was no 36 
difference for quality of life (EQ-5D visual analogue scale (VAS): + 6.2 (95% CI: -5.7 to 18.1 higher), 1 study, 37 
low quality), LOS  (+1.3 hours (-108.96 to 111.56), 1 study, moderate quality), or number of future hospital 38 
admissions (- 0.1 admissions per patient (95% CI: -0.38 to 0.18), 1 study, low quality) and a possible increase in 39 
mortality at 3 months (RR= 1.57 (95% CI: 0.55 to 4.46), 1 study, very low quality). The results are summarised 40 
in the clinical evidence profile in Table 5.3 in Appendix 5 and the Forest plots presented in Appendix 6 of the 41 
Supplementary Materials. 42 
One comparative cost analysis (CCA) conducted in the UK showed that pharmacist input at admission was cost 43 
saving compared to usual care (mean saving of £142 per patient).34 The analysis was assessed as partially 44 
applicable with potentially serious limitations. The results are summarised in Table 5.4, Appendix 5 and the 45 
quality assessment rationale in Appendix 7 in the Supplementary Material. 46 
Ward-based pharmacist input at discharge 47 
Four RCTs (n=770) evaluated provision of ward-based pharmacists’ input at discharge.15 16 18 27 The pharmacists 48 
in the intervention arm in these studies were involved only at the discharge stage, for example preparing 49 
patients’ medications and providing counselling before discharge. The evidence suggested a benefit in terms of 50 
reduced prescription errors (RR 0.57 (95% CI: 0.37 to 0.88), 1 study, low quality), reduced readmissions up to 51 
22 days post discharge (RR 0.36 (95% CI: 0.14 to 0.91), 1 study, very low quality) and drug therapy 52 
inconsistencies and omissions at discharge (RR 0.06 (95% CI: 0.01 to 0.44), 1 study, moderate quality). There 53 
was no evidence of effect on quality of life (EQ-5D VAS: 2.8 (95% CI: -1.83 to 7.43), EQ-5D index: 0.05 54 
higher (95% CI: -0.05 to 0.15), 1 study, very low to low quality). The results are summarised in the clinical 55 
evidence profile in Appendix 5, Table 5.3, and the Forest plots presented in Appendix 6 of the Supplementary 56 
Materials. 57 
One CUA, conducted in Sweden, showed that the ward-based pharmacist input at discharge was not cost 58 
effective, with an ICER of £327,378 per adjusted QALY gained.38 The analysis was assessed as partially 59 
applicable with minor limitations. The results are summarised in Appendix 5, Table 5.4 and the quality 60 
assessment rationale in Appendix 7 of the Supplementary Materials. 61 
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DISCUSSION 62 
Medication prescribing is the most common healthcare intervention for a patient, and is normally the main 63 
course of treatment for the vast majority. The hospital pharmacist is central to ensuring the quality and safety of 64 
this process. Pharmacist input can be crucial at all stages of the patient journey with different interventions at 65 
each stage. Hence, we stratified the evidence by whether the pharmacist input occurred throughout the patient 66 
stay or was only at admission or discharge. The reviewed evidence for all three strata demonstrated some 67 
benefits for ward-based hospital pharmacist input, although there was variation in the intensity of the 68 
interventions and composition of the comparators. The evidence was of very low to moderate quality due to risk 69 
of bias, imprecision and inconsistency for regular ward-based pharmacist input and ward-based pharmacist input 70 
at discharge. The evidence reviewed for ward-based pharmacist input at admission was of very low to moderate 71 
quality due to risk of bias, imprecision and outcome indirectness as the outcome ‘agreement with prescriber’ 72 
was used as a surrogate outcome for staff satisfaction and was considered an indirect outcome.  73 
The health economic evidence was assessed to be partially applicable (with only 2 studies from the UK and 3 74 
reporting QALYs, which is the outcome measure preferred by NICE). However, it is acknowledged that quality 75 
of life is an outcome that may not be sensitive to pharmacist interventions. Hence, studies reporting other 76 
outcomes were also considered by the committee when making the recommendations. 77 
The evidence was also considered to have potentially serious limitations with none of the studies being based on 78 
a review of the evidence base and the cost components included being variable. No clinical or economic 79 
evidence was found relating to 7-day provision of ward-based pharmacist input. 80 
Studies assessing the clinical and economic outcomes of the ward-based, clinical pharmacist role have been 81 
accumulating over the years. These studies have generally focused on the effect of pharmacist interventions on 82 
medication errors, medicines reconciliation and savings achieved from reduced medication waste and more 83 
appropriate prescribing. A number of reviews have assessed this evidence in an attempt to draw conclusions 84 
regarding impact on patient outcomes.39 40 In line with our findings, these reviews have generally shown positive 85 
outcomes including reduced prescribing errors, reduced LOS, reduced admission, and improved patient 86 
satisfaction and physician agreement to act upon medication discrepancies identified. However, overall, the 87 
evidence was relatively weak. The evidence was based mainly on studies with small sample sizes, which 88 
contributed to the high risk of bias in the study outcomes and imprecision around the effect estimates.  89 
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The mechanism by which pharmacists might improve patient outcomes would most likely be through 90 
minimising prescribing errors, by ensuring appropriate prescribing and also by deprescribing/discontinuation of 91 
drugs. Pharmacist education and input is also likely to improve patient and/or carer satisfaction.41 Evidence was 92 
found for these outcomes, though not in all strata and with some inconsistencies. For example, some evidence 93 
showed increased prescribing errors at 30 days post discharge, measured by research (rather than intervention) 94 
pharmacists according to the medication appropriateness index and adverse drug events at 3 to 6 months post 95 
discharge. These findings, though unexpected, suggest that the experience of the pharmacist and their 96 
integration in the ward team are likely important factors in achieving positive outcomes, because the 97 
pharmacists in the study reporting this findings were junior pharmacists and new to the ward team. The impact 98 
on quality of life was also modest, which is likely to be due to the acute nature of illness and the short follow-up 99 
periods. 100 
Prescription and administration errors are amongst the most commonly identified adverse events during a 101 
patient’s stay in hospital.42 Pharmacists, as part of the multidisciplinary team, can reduce these errors and ensure 102 
that the patient gets the correct treatment, as well as discontinuing drugs which are no longer required in both 103 
the short and long term. The pharmacist has an important educational role which has the potential to improve 104 
patients’ adherence after discharge. These activities allow doctors to focus on other key patient care priorities. 105 
It is also acknowledged with the aging population that there is an increasing number of patients with multi-106 
morbidities who are exposed to poly-pharmacy.8 In this situation the pharmacist can play a vital role in advising 107 
the medical team regarding drugs and how to prescribe treatment optimally. Involving the pharmacist at hospital 108 
discharge may have reduced the need for junior doctors to explain prescribing regimens, and the need for the 109 
patient to visit their general practitioner following discharge for drug review. This would improve patient and/or 110 
carer satisfaction and have a potential cost benefit. 111 
Pharmacists are also gradually acquiring independent prescribing rights.43 44 This allows them to correct 112 
prescribing errors or make changes directly without the need for doctor involvement. Streamlining the 113 
prescribing of medications to take home at the end of hospital stay could also facilitate earlier discharge and 114 
allow junior doctors to focus on other tasks produced from the ward rounds.45 Assessment of the cost 115 
effectiveness of prescribing pharmacists in hospital should include these considerations. 116 
The cost effectiveness of the ward-based pharmacist role has been assessed in a number of published economic 117 
evaluations. However, unlike the evidence for clinical effectiveness, the generalisability of the findings of these 118 
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evaluations from one health care system to another might be limited due to the different funding arrangements 119 
and the perspectives used in the analysis.46-48  120 
The economic evidence in our review was in favour of the provision of ward-based pharmacist input but the 121 
interventions, and therefore results, varied from one country to another. Clinical pharmacists in the reviewed 122 
UK studies were generally experienced (band 7/8) and have specialist knowledge in the medications they 123 
managed. They also were completely integrated in their clinical teams.36 This may not be the same profile in the 124 
non-UK studies. Additionally, the standard care/control arm in the included economic studies was not always 125 
clearly defined and was variable in terms of the level of pharmacist input. Some studies included a specified 126 
level of clinical pharmacist input in the control group which was enhanced in the intervention group (for 127 
example, by attendance at ward rounds) while others described the introduction of a completely new service. 128 
These differences might explain the differences in the findings of these studies, which has also been highlighted 129 
by other reviews of this evidence.47 130 
With the exception of the UK economic modelling study,36 all economic studies had a follow-up of 12 months 131 
or less and hence would not have assessed the long term impact of the ward-based pharmacist intervention. 132 
Additionally, the majority of the studies assessed a limited number of cost categories; focusing on medication 133 
costs, pharmacist time and less on other staff time (e.g. freeing up or release of junior doctor time) and patient-134 
related downstream costs. 135 
There was evidence that pharmacist input throughout the hospital stay would achieve saving in terms of 136 
medications costs, which was the most frequently assessed cost category in the included studies. One study 137 
found the pharmacist cost was completely offset by medication cost savings.21 The evidence was less clear in 138 
terms of impact on other staff time and on long-term patient outcomes, which were not always assessed in the 139 
included studies. Where this impact was quantified, the results showed potential for cost saving. Avoiding 140 
medication errors that have severe consequences is also an important positive outcome in terms of avoiding 141 
litigation costs.36 Overall, the economic evidence suggested that the regular input by ward-based pharmacists is 142 
cost-effective. Pharmacist input only at discharge was not cost effective, but the evidence for this was limited to 143 
one Swedish study.38 144 
This systematic review demonstrates the potential benefits for patient safety of including ward-based 145 
pharmacists in the multidisciplinary team in hospital.  Our focus on higher-quality studies permits robust 146 
conclusions.  However, sample sizes tended to be small, there was some heterogeneity between the interventions 147 
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studied, and we did not formally assess publication bias.  Nevertheless, our findings are consistent with earlier 148 
reviews and have strong face-validity, allowing the guideline committee to recommend the routine inclusion of 149 
ward-based pharmacists in the multidisciplinary team managing acutely ill hospitalised patients.49 150 
CONCLUSION 151 
Evaluations of the ward-based pharmacist input have largely found it to be both effective and cost effective, 152 
particularly when provided throughout the different stages of the patient journey by experienced pharmacists 153 
who are integrated in the ward team. The effectiveness evidence, however, was generally of low quality. The 154 
economic evidence had potentially serious limitations. The interventions and comparators were often not well 155 
defined and there was variation across the studies in their composition. 156 
Nevertheless, the collective body of the available evidence suggests that recommending regular ward-based 157 
pharmacist input and inclusion in the multidisciplinary team would offer additional value to the provision of 158 
care for those admitted for a suspected or confirmed medical emergency. However, further research is needed to 159 
determine the optimal level of involvement of ward-based pharmacists and to assess whether the provision of a 160 
7-day service is cost-effective. 161 
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